» Articles » PMID: 26777049

A Novel De Novo GATA Binding Protein 3 Mutation in a Turkish Boy with Hypoparathyroidism, Deafness, and Renal Dysplasia Syndrome

Overview
Date 2016 Jan 19
PMID 26777049
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Hypoparathyroidism, deafness, and renal dysplasia (HDR; OMIM 146255) syndrome is a rare disease, inherited dominantly and found to be related with GATA3 (GATA binding protein 3) gene mutations. A 13-year and 8-month-old boy who presented with hypocalcemia was diagnosed with hypoparathyroidism. He also had dysmorphic facial features, renal anomaly (pelvic kidney), and mild sensorineural hearing loss. His cranial computed tomography revealed multiple calcifications in bilateral centrum semiovale, corona radiata, and basal ganglions suggesting a persistent hypoparathyroidism. Thus, the presence of triad of HDR syndrome was considered, and genetic analysis using a next-generation sequencer identified a novel de novo missense mutation in exon 4 p.R276Q (c.827G>A) of GATA3 gene. This is the second patient who was reported to have a mutation in GATA3 gene from Turkey. In conclusion, although HDR syndrome is a rare condition, it should be kept in mind in patients with hypoparathyroidism. Classical triad can easily be identified if patients diagnosed with hypoparathyroidism are also evaluated with a urinary tract ultrasound and an audiometer.

Citing Articles

A novel frameshift variant of GATA3 (p.Ala17ProfsTer178) responsible for HDR syndrome in a Japanese family.

Hasegawa Y, Segawa T, Chida A, Yoshida E, Kinno H, Chiba H Endocr J. 2024; 71(11):1077-1086.

PMID: 39198190 PMC: 11778358. DOI: 10.1507/endocrj.EJ24-0147.


A Novel Mutation in Gene in a Case of Hypoparathyroidism, Deafness, and Renal Dysplasia Syndrome.

Prabhu P, Ballal S, Augustine R, Shetty M Indian J Nephrol. 2023; 33(5):377-380.

PMID: 37881737 PMC: 10593303. DOI: 10.4103/ijn.ijn_250_21.


Hypoparathyroidism, Sensorineural deafness and renal disease (Barakat syndrome) caused by a reduced gene dosage in GATA3: a case report and review of literature.

Joseph A, Sirisena N, Kumanan T, Sujanitha V, Strelow V, Yamamoto R BMC Endocr Disord. 2019; 19(1):111.

PMID: 31660939 PMC: 6816161. DOI: 10.1186/s12902-019-0438-4.

References
1.
Kobayashi H, Kasahara M, Hino M, Yoshimura H, Takahara S, Ikeda K . A novel heterozygous deletion frameshift mutation of GATA3 in a Japanese kindred with the hypoparathyroidism, deafness and renal dysplasia syndrome. J Endocrinol Invest. 2006; 29(9):851-3. DOI: 10.1007/BF03347383. View

2.
Gaynor K, Grigorieva I, Nesbit M, Cranston T, Gomes T, Gortner L . A missense GATA3 mutation, Thr272Ile, causes the hypoparathyroidism, deafness, and renal dysplasia syndrome. J Clin Endocrinol Metab. 2009; 94(10):3897-904. DOI: 10.1210/jc.2009-0717. View

3.
Van Esch H, Devriendt K . Transcription factor GATA3 and the human HDR syndrome. Cell Mol Life Sci. 2001; 58(9):1296-300. PMC: 11337399. DOI: 10.1007/pl00000940. View

4.
Al-Shibli A, Al Attrach I, Willems P . Novel DNA mutation in the GATA3 gene in an Emirati boy with HDR syndrome and hypomagnesemia. Pediatr Nephrol. 2011; 26(7):1167-70. DOI: 10.1007/s00467-011-1835-8. View

5.
Fukami M, Muroya K, Miyake T, Iso M, Kato F, Yokoi H . GATA3 abnormalities in six patients with HDR syndrome. Endocr J. 2011; 58(2):117-21. DOI: 10.1507/endocrj.k10e-234. View